SCHEDULE 13G/A 0001104659-22-022115 0001747821 XXXXXXXX LIVE 3 Ordinary Shares, par value $0.0001 per share 12/31/2025 0001677940 BEYONDSPRING INC. G10830100 100 Campus Drive, West Side 4th Floor, Suite 410 Florham Park NJ 07932 Rule 13d-1(c) Decheng Capital Management III (Cayman), LLC b E9 0.00 1448293.00 0.00 1448293.00 1448293.00 3.5 OO Decheng Capital China Life Sciences USD Fund III, L.P. b E9 0.00 1448293.00 0.00 1448293.00 1448293.00 3.5 PN Decheng Capital China Life Sciences USD Fund II, L.P. b E9 0.00 1617409.00 0.00 1617409.00 1617409.00 3.9 PN Decheng Capital Management II (Cayman), LLC b E9 0.00 1617409.00 0.00 1617409.00 1617409.00 3.9 OO Decheng Capital Global Healthcare Fund (Master), LP b E9 0.00 735000.00 0.00 735000.00 735000.00 1.8 PN Decheng Capital Global Healthcare GP, LLC b E9 0.00 735000.00 0.00 735000.00 735000.00 1.8 OO Xiangmin Cui b X1 0.00 3800702.00 0.00 3800702.00 3800702.00 9.2 IN BEYONDSPRING INC. 100 Campus Drive, West Side, 4th Floor, Suite 410, Florham Park, NJ, 07932. Decheng Capital China Life Sciences USD Fund II, L.P. ("Fund II") Decheng Capital Management II (Cayman), LLC ("GP II") Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III") Decheng Capital Management III (Cayman), LLC ("GP III") Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare") Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") Xiangmin Cui ("Dr. Cui") c/o Decheng Capital 3000 Sand Hill Road, Building 2, Suite 110 Menlo Park, CA 94025 Fund II Cayman Islands GP II Cayman Islands Fund III Cayman Islands GP III Cayman Islands Healthcare Cayman Islands Healthcare GP Cayman Islands Dr. Cui United States Y Row 9 of each Reporting Person's cover page to this Schedule 13G/A sets forth the aggregate number of ordinary shares of the Issuer beneficially owned by such Reporting Person as of December 31, 2025 and is incorporated by reference. The Reporting Persons' ownership of the Issuer's securities consists of (i) 1,448,293 ordinary shares held directly by Fund IIII; (ii) 1,617,409 ordinary shares held directly by Fund II; and (iii) 735,000 ordinary shares held directly by Healthcare. GP II is the general partner of Fund II and shares voting and investment authority over the shares held by Fund II. GP III is the general partner of Fund III and shares voting and investment authority over the shares held by Fund III. Healthcare GP is the general partner of Healthcare and shares voting and investment authority over the shares held by Healthcare. Dr. Cui is the sole manager of each of GP II and GP III and the indirect managing member and ultimate beneficial owner of Healthcare GP. Dr. Cui shares voting and investment authority over the shares held by each of Fund II, Fund III and Healthcare. Row 11 of each Reporting Person's cover page to this Schedule 13G/A sets forth the percentages of the ordinary shares of the Issuer beneficially owned by such Reporting Person as of December 31, 2025, and is incorporated by reference. The percentage set forth in each row 11 is based upon 41,122,320 ordinary shares outstanding as of November 18, 2025, as reported in the Issuer's prospectus supplement dated November 17, 2025 filed with the Securities and Exchange Commission (the "SEC") on November 17, 2025. Row 5 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of December 31, 2025 and is incorporated by reference. Row 6 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of December 31, 2025 and is incorporated by reference. Row 7 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of December 31, 2025 and is incorporated by reference. Row 8 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of December 31, 2025 and is incorporated by reference. Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Exhibit 99.1 Joint Filing Agreement, dated as of November 14, 2024, (incorporated by reference to Exhibit A to the Reporting Persons' Schedule 13G filed with the SEC on November 14, 2024). Decheng Capital Management III (Cayman), LLC /s/ Xiangmin Cui 02/13/2026 Decheng Capital China Life Sciences USD Fund III, L.P. /s/ Xiangmin Cui 02/13/2026 Decheng Capital China Life Sciences USD Fund II, L.P. /s/ Xiangmin Cui 02/13/2026 Decheng Capital Management II (Cayman), LLC /s/ Xiangmin Cui 02/13/2026 Decheng Capital Global Healthcare Fund (Master), LP /s/ Xiangmin Cui 02/13/2026 Decheng Capital Global Healthcare GP, LLC /s/ Xiangmin Cui 02/13/2026 Xiangmin Cui /s/ Xiangmin Cui 02/13/2026